ArticleAsian Pacific journal of cancer prevention : APJCP2025
CYP2D6 and CYP2E1 Gene Polymorphisms and Their Influence on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Genotype to Functional Risk: A Multi-Omic Approach to Predicting Thiopurine and Methotrexate Co-Therapy-Induced Liver Injury.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe majority of breast cancer cases are treated with invasive chemotherapy, which typically involves combinations of drugs as part of the standard therapeutic regimen. However, responses to chemotherapeutic agents and treatment outcomes can vary significantly among patients, and the occurrence of acute toxicity remains unpredictable. Phase I drug detoxification genes, such as those encoding cytochrome P450 enzymes, play a crucial role in the metabolism of chemotherapeutic drugs in cancer patients. Therefore, this study aimed to investigate polymorphisms in the CYP2D6 and CYP2E1 genes and their potential association with adverse reactions to doxorubicin and paclitaxel-based chemotherapy in breast cancer patients. MATERIALS &
methodsGenotyping of CYP2D6*3, CYP2D6*4, CYP2D6*10, CYP2D6*17, CYP2E1*5B, CYP2E1*6, CYP2E1*7B genes was performed among 200 breast cancer patients undergoing chemotherapy, using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The association between gene polymorphisms and chemotherapy-induced toxicity was assessed using odds ratios (ORs) with 95% confidence intervals and corresponding p-values, where p ≤ 0.05 was considered statistically significant.
resultsFollowing the analysis of CYP2D6 and CYP2E1 gene polymorphisms, we observed that CYP2D6*4 (rs3892097, G>A) (OR = 4.71; 95% CI: 1.93-11.46; p = 0.0006), CYP2D6*10 (rs1065852, C>T) (OR = 3.43; 95% CI: 1.43-8.21; p = 0.005), and CYP2E1*6 (rs6413432, T>A) (OR = 4.00; 95% CI: 1.66-9.61; p = 0.001) showed a positive association with severe peripheral neuropathy induced by paclitaxel-based chemotherapy in breast cancer patients. Additionally, CYP2E1*6 (rs6413432, T>A) (OR = 4.04; 95% CI: 1.72-9.50; p = 0.001) was significantly associated with paclitaxel-induced body ache in a subset of breast cancer patients.
conclusionThe findings from this study conclude that polymorphisms in the CYP2D6 and CYP2E1 genes are associated with peripheral neuropathy, a non-hematological toxicity reaction, in breast cancer patients receiving paclitaxel-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.